Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

10 Worst Performing Small-Cap Stocks In March 2022

Published 04/08/2022, 01:20 AM

Small-cap stocks are companies with a market capitalization between $300 million and $2 billion. Historically, such stocks have performed better than large-cap stocks, especially during financial crises. Though these stocks offer higher returns, they are equally risky as well because of their higher volatility.

If a trade goes wrong, investors can lose a significant amount of money by betting on small-cap stocks. To give you an idea of the extent of losses, discussed below are the ten worst performing small-cap stocks in March 2022. We have used the March return data of small-cap stocks (from finviz.com) to rank the ten worst-performing small-cap stocks in March 2022, in reverse order.

  1. LiveVox Holding (-37%)

Founded in 2014 and headquartered in San Francisco, this company develops cloud-based contact center platforms for healthcare, financial services, telecom, customer care, and other industries. LiveVox Holdings Inc (NASDAQ:LVOX) shares are down almost 39% YTD and almost 69% in the last year. Its shares are currently trading around $3.15, while it has a 52-week range of $2.5 and $10.39. As of writing, LiveVox Holding’s market cap was more than $290 million.

  1. Blend Labs (-38%)

Founded in 2012 and headquartered in San Francisco, this company offers a cloud-based software platform for financial services firms to support banking products. Blend Labs shares are down almost 37% YTD. Its shares are currently trading around $4.87, while it has a 52-week range of $4.45 and $21.04. As of writing, Blend Labs’ market cap was more than $1.10 billion.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
  1. Graphite Bio (-39%)

Founded in 2017 and headquartered in South San Francisco, it is a clinical-stage gene-editing company that focuses on therapies harnessing targeted gene integration to treat or cure serious diseases. Graphite Bio Inc (NASDAQ:GRPH) shares are down over 64% YTD. Its shares are currently trading around $4.5, while it has a 52-week range of $4.40 and $34. As of writing, Graphite Bio’s market cap was more than $270 million.

  1. NeoGenomics (-42%)

Founded in 1998 and headquartered in Fort Myers, Fla., a clinical laboratory company that deals in cancer genetics diagnostic testing and pharma services. NeoGenomics Inc (NASDAQ:NEO) has two business segments: Clinical Services and Pharma Services. NeoGenomics shares are down over 66% YTD and over 70% last year. Its shares are currently trading around $11.80, while it has a 52-week range of $11.00 and $54.74. As of writing, NeoGenomics’ market cap was more than $1.4 billion.

  1. Omega Therapeutics (-43%)

Founded in 2016 and headquartered in Cambridge, Mass., this company develops DNA-sequence-targeting and mRNA-encoded therapeutics and offers its product under the OMEGA platform. Omega Therapeutics Inc (NASDAQ:OMGA) shares are down almost 49% YTD. Its shares are currently trading around $6.12, while it has a 52-week range of $6.01 and $31.41. As of writing, Omega Therapeutics’ market cap was more than $300 million.

  1. Nektar Therapeutics (-50%)

Founded in 1990 and headquartered in San Francisco, it is a biopharmaceutical company that develops and discovers medicines in areas of oncology, immunology, and virology. Nektar Therapeutics (NASDAQ:NKTR) shares are down almost 58% YTD and over 70% in the last year. Its shares are currently trading around $5.61, while it has a 52-week range of $3.88 and $20.66. As of writing, Nektar Therapeutics’ market cap was more than $1 billion.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
  1. Amylyx Pharmaceuticals (-54%)

Founded in 2013 and headquartered in Cambridge, Mass., it is a biopharmaceutical company that offers disease-modifying solutions for neurodegenerative diseases focusing on streamlined clinical development and drug discovery. Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) shares have been up to over 7% in the last five days. Its shares are currently trading around $13.30, while it has a 52-week range of $10.49 and $33.41. As of writing, Amylyx Pharmaceuticals’ market cap was more than $740 million.

  1. Cepton (-59%)

Founded in 2016 and headquartered in San Jose, Calif., this company develops and commercializes lidar and imaging technologies for automotive and smart infrastructure industries. Cepton Inc (NASDAQ:CPTN) shares are down almost 63% YTD and over 62% in the last year. Its shares are currently trading around $3.71, while it has a 52-week range of $3.62 and $80.16. As of writing, Cepton’s market cap was more than $590 million.

  1. Icosavax (-60%)

Founded in 2017 and headquartered in Seattle, this company develops and commercializes vaccines against infectious diseases, especially vaccines for viral causes of pneumonia in older adults. Icosavax Inc (NASDAQ:ICVX) shares are down almost 67% YTD. Its shares are currently trading around $7.77, while it has a 52-week range of $4 and $49.99. As of writing, Icosavax’s market cap was more than $250 million.

  1. Inspirato (-80%)

Founded in 2011 and headquartered in Denver, it is a travel subscription company that offers users access to hand-selected vacation options through a subscription model. Inspirato Inc (NASDAQ:ISPO) shares are down over 19% YTD and almost 18% in the last year. Its shares are currently trading around $8.17, while it has a 52-week range of $7.70 and $108. As of writing, Inspirato's market cap was more than $1 billion.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.